Abstract
A model system has been used to test the efficacy of vascular targeting of α-particle emitter213Bi for therapy of small, ‘artificial’ metastases in mouse lung. Specific monoclonal antibody (mAb) 201B was used to deliver greater than 30% of the injected dose to lung where tumours had developed due to intravenous injection of cells. Specific213Bi-mAb 201B treatment of BALB/c mammary carcinoma EMT-6 tumours in lung resulted in a dose-dependent destruction of tumours and an extended lifespan of treated animals relative to controls. Significant reduction of lung tumour burden was noted in animals treated with 0.93 MBq injected dose or as little as 14 Gy absorbed dose to the lung. Animals treated with higher doses (2.6–6.7 MBq) had nearly complete cure of lung tumours but eventually died of lung fibrosis induced by the treatment. Four other tumour cell types were studied: murine Line 1 lung carcinomas in syngeneic BALB/c mice, rat IC-12 tracheal carcinoma growing in severe combined immune deficient (SCID) mice, and two human tumours – epidermoid carcinoma A431 and lung carcinoma A549 – growing in SCID mice. In all cases, the number of lung tumour colonies was reduced in animals treated with specific, labelled mAb relative to those in animals treated with control213Bi MAb or EDTA complexed213Bi. Tumours treated in immunodeficient SCID mice were partially destroyed or at least retarded in growth, but ultimately regrew and proved fatal, indicating that an intact immune function is necessary for complete cure. The data show that the short-lived α-particle emitter213Bi can be effectively targeted to lung blood vessels and that tumour cells growing in the lung are killed. The mechanism may involve direct killing of tumour cells from α-particle irradiation, killing through destruction of blood supply to the tumour, or a combination of the two.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adamson, I. Y. R., Bowden, D. H., Cote, M. G. & Witschi, H. P. (1977) Lung injury induced by butylated hydroxytoluene. Lab Invest 36: 26–32.
Blumenthal, R. D., Sharkey, R. M., Haywood, L., Natale, A. M., Wong, G. Y., Siegel, J. A., Kennel, S. J. & Goldenberg, D. M. (1992) Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with131I-labeled monoclonal antibodies. Cancer Res 52: 6036–6044.
Boll, R. A., Mirzadeh, S. & Kennel, S. J. (1997) Optimization of radiolabeling of immunoproteins with213Bi. Radiochimica Acta 79: 145–149.
Borgström, P., Hillan, K. J., Sriramarao, P. & Ferrara, N. (1996) Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032–4039.
Brechbiel, M. W. & Gansow, O. A. (1992) Synthesis of C-functionalized trans- cyclohexyldiethylenetriaminepenta-acetic acids for labeling of monoclonal antibodies with the bismuth-212 α particle emitter. J Chem Soc Perkin Trans I 1: 1173–1178.
Briesmeister, J. (1993). MCNP-A general Monte Carlo n-particle transport code. NCNP User’s Manual. Los Alamos National Laboratory: Los Alamos, CA
Burrows, F. J. & Thorpe, P. E. (1994) Vascular targeting: a new approach to the therapy of solid tumours. Pharmacol Ther 64: 155–174.
Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S. & Thorpe, P. E. (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1: 1623–1634.
Denekamp, J. (1984) Vasculature as a target for tumor therapy. Prog. Appl Microcirc 4: 28–38.
Epstein, A. L., Khawli, L. A., Hornick, J. L. & Taylor, C. R. (1995) Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res 55: 2673–2680.
Foster, D. & Barrett, P. (1997). Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAM II software system. In:Proc. Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge Institute for Science and Education: Knokvitte, TN
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H. & Parks, W. P. (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51: 1417–1423.
Hartmann, F., Horak, E. M., Garmestani, K., Wu, C., Brechbiel, M. W., Kozak, R. W., Tso, J., Kosteiny, S. A., Gansow, O. A., Nelson, D. L. & Waldmann, T. A. (1994) Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 54: 4362–4370.
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S. & Thorpe, P. E. (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547–550.
Hughes, B. J., Kennel, S., Lee, R. & Huang, L. (1989) Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res 49: 6214–6220.
Humm, J. L. (1987) A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 13: 1767–1773.
Huneke, R. B., Pippin, C. G., Squire, R. A., Brechbiel, M. W., Gansow, O. A. & Strand, M. (1992) Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 52: 5818–5820.
Kennel, S. J., Lankford, T., Hughes, B. & Hotchkiss, J. A. (1988) Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. Lab Invest 59: 692–701.
Kennel, S. J., Lee, R., Bultman, S. & Kabalka, G. (1990) Rat monoclonal antibody distribution in mice: An epitope inside the lung vascular space mediates very efficient localization. Nucl Med Biol 17: 193–200.
Kennel, S. J. & Mirzadeh, S. (1997) Vascular targeting for radioimmunotherapy with213Bi. Radiochimica Acta 79: 87–91.
Kennel, S. J. & Mirzadeh, S. (1998) Vascular targeted radioimmunotherapy with213Bi: an alpha particle emitter. Nucl Med Biol 25: 241–246.
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S. & Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841–844.
Korbelik, M., Krosi, G., Krosi, J. & Dougherty, G. J. (1996) The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 56: 5647–5652.
Loevinger, R., Budinger, T. & Watson, E. (1988). MIRD primer for absorbed dose calculations. The Society of Nuclear Medicine Inc: New York
Mori, A., Kennel, S. J., Waalkes M v, B., Scherphof, G. L. & Huang, L. (1995) Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model. Cancer Chemother. Pharmacol 35: 447–456.
O’Reilly, M. S., Brem, H. & Folkman, J. (1995) Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 30: 325–330.
O’Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R. & Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–28.
Pasqualini, R. & Ruoslahti, E. (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380: 364–366.
Rockwell, S. C., Kallman, R. F. & Fajardo, L. F. (1972) Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 49: 735–749.
Speidel, M. T., Holmquist, B., Kassis, A. I., Humm, J. L., Berman, R. M., Atcher, R. W., Hines, J. J. & Macklis, R. M. (1993) Morphological, biochemical, and molecular changes in endothelial cells after alpha-particle irradiation. Radiation Res 136: 373–381.
Terzaghi-Howe, M. (1987) Inhibition of carcinogen-altered rat tracheal epithelial cell proliferation by normal epithelial cells in vivo. Carcinogenesis 8: 145–150.
Yoriyaz, H. & Stabin, M. (1997) Electron and photon transport in a model of a 30-g mouse. J Nucl Med 38: 228
Yuhas, J. M., Tyoa, R. E. & Wagner, E. (1975) Specific and nonspecific stimulation of resistance to the growth and metastasis of the line 1 lung carcinoma. Cancer Res 35: 242–244.
Zalutsky, M. R., McLendon, R. E., Garg, P. K., Archer, G. E., Schuster, J. M. & Bigner, D. D. (1994) Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 54: 4719–4725.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kennel, S., Boll, R., Stabin, M. et al. Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi. Br J Cancer 80, 175–184 (1999). https://doi.org/10.1038/sj.bjc.6690337
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690337
Keywords
This article is cited by
-
Targeted α-therapy in non-prostate malignancies
European Journal of Nuclear Medicine and Molecular Imaging (2021)
-
Extraction chromatographic behavior of actinium and REE on DGA, Ln and TRU resins in nitric acid solutions
Journal of Radioanalytical and Nuclear Chemistry (2015)
-
Studies of the Pharmacokinetics of Actinium-255-Labeled Bisphosphonate in Intact Mice
Pharmaceutical Chemistry Journal (2013)
-
Guidelines for the welfare and use of animals in cancer research
British Journal of Cancer (2010)
-
Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer
Clinical & Experimental Metastasis (2005)